JP Morgan Maintains Neutral on Conmed, Raises Price Target to $50
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and raises the price target from $45 to $50.
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and raises the price target from $45 to $50.